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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: This study aimed to evaluate the association between highly
active antiretroviral therapy (HAART) adherence and development of Kaposi’s sarcoma (KS) in
human immunodeficiency virus (HIV)/AIDS patients.
Methods: We conducted a retrospective nested caseecontrol study of 165 participants (33
cases and 132 controls) receiving HAART care at Maseno Hospital, Kenya, from January 2005
to October 2013. Cases were HIV-positive adults with KS, who were matched with controls
in a ratio of 1:4 based on age (5 years of each case), sex, and KS diagnosis date. Perfect
adherence to HAART was assessed on every clinic visit by patients’ self-reporting and pill
counts. Chi-square tests were performed to compare socioeconomic and clinical statuses be-
tween cases and controls. A conditional logistic regression was used to assess the effects of
perfect adherence to HAART, the latest CD4 count, education level, distance to health-care
facility, initial World Health Organization stage, and number of regular sexual partners on
the development of KS.
Results: Only 63.6% participants reported perfect adherence, and the control group had a
significantly higher percentage of perfect adherence (75.0%) than did cases (18.2%). Afterram in Global Health and Development, College of Public Health and Nutrition, Taipei Medical Uni-
ity 110, Taiwan.
u.tw (F.-J. Tsai).
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http://dx.doi.org/10.1016/j.jmii.201adjustment for potential imbalances in the baseline and clinical characteristics, patients with
imperfect HAART adherence had 20-times greater risk of developing KS than patients with per-
fect HAART adherence [hazard ratios: 21.0, 95% confidence interval: 4.2e105.1]. Patients with
low latest CD4 count (350 cells/mm3) had a seven-times greater risk of developing KS than
did their counterparts (HRs: 7.1, 95% CI: 1.4e36.2).
Conclusion: Imperfect HAART adherence and low latest CD4 count are significantly associated
with KS development.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Kaposi’s sarcoma (KS) is one of the defining features of AIDS
since 1982.1 It is known to cause deep-purple skin lesions
that can be disfiguring and can also be fatal if the cancer
spreads to the lungs and other organs.2 Once traditionally
considered a slow-growing malignancy, KS continues to be a
global scourge since the advent of the human immunode-
ficiency virus (HIV) pandemic, and it is currently one of the
most commonly diagnosed cancers among HIV-infected
persons in Africa.3e5 Since it became available in 1996,
the use of highly active antiretroviral therapy (HAART) to
treat HIV infections has led to decreases in KS mortality
rates in resource-limited settings and to increases in the
number of persons living with HIV infection.1,6 However,
the disease still develops in approximately 15% of AIDS
patients.7,8
HAART is a lifelong therapy, and its success in reducing
the viral load to undetectable levels by current blood
testing techniques relies on continual adherence to medi-
cations.9,10 According to the World Health Report 2003, the
consequences of imperfect medication adherence are so
huge that people across the world would benefit more from
efforts aimed at improving medication adherence than
from the development of new medical treatments.11,12
According to a previous study, acceptable adherence
rates of HAART are 90e95% to avoid rapid treatment fail-
ure, which ultimately leads to disease development.13
Treatment efficacy relies, however, on sustained adher-
ence, which constitutes a serious challenge to those
receiving HAART.
The regimens are often complicated and can include
varying dosing schedules, dietary restrictions, and adverse
effects.14,15 As more patients are initiated on lifelong
HAART, one of the major future challenges, apart from
securing sustainable funding, lies in retaining patients in
care and sustaining adherence to HAART.16 Although the
close linkage of AIDS and KS and the importance of HAART
adherence for AIDS control were pointed out by various
studies, to our knowledge, no study has evaluated the
relationship between HAART adherence and KS
development.
In Africa, there have been comparatively few published
studies or data on KS treatment and epidemiology. Ac-
cording to a recent report, about 80,000 cases of cancer are
diagnosed each year. Of all the cancers registered, KS
accounted for 6.9% of the total cases.17 While Kenya is atLupia R, et al., Risk factors for K
A nested caseecontrol study in K
5.10.009the epicenter of the HIV/AIDS epidemic with approximately
1.6 million people currently living with the virus, this con-
dition has emerged as a priority that needs to be studied.
Therefore, we conducted this study in Kenya to evaluate
the association between HAART medication adherence and
the development of KS in HIV/AIDS patients.
Materials and Methods
We conducted a retrospective nested caseecontrol study of
KS patients receiving primary care at the Maseno Hospital
Comprehensive Care Clinic, Kenya, from January 2005 to
October 2013.
Data source
This study was conducted at the Maseno Comprehensive
Care Clinic in Maseno Hospital, which is situated in the
western part of Kenya. Maseno Hospital was established in
1906 with a capacity of 175 beds, and the comprehensive
care clinic was set up in 2005 to cater to HIV/AIDS patients.
The clinic has had 4330 patients enrolled in the program
since its inception in 2005.
Medical records of patients are captured and stored in the
International Quality Care Tool, a patient management
electronic medical record database recommended by the
World Health Organization (WHO).17e19 The information used
in this study was collected from this electronic database.
At enrollment, patients routinely have clinical, labora-
tory, and radiological evaluations including a physical ex-
amination, full blood count, alanine transaminase, serum
creatinine, Venereal Disease Research Laboratory test, CD4
count, and a chest X-ray. The CD4 count is monitored every
6 months. The viral load is only performed when treatment
failure is suspected, based on clinical and immunological
parameters. HAART is typically initiated when the CD4
count is  350/mL in line with national and WHO guidelines
or if the patient is in WHO Clinical Stage 3 or 4 regardless of
the CD4 count.
Definition of cases and the matching process
Cases were defined as HIV-positive adults with KS receiving
HAART care at the comprehensive care clinic. The
morphology code of the International Classification of Dis-
ease (ICD)-10 for KS (M9140/3) was used to identify cases.aposi’s sarcoma in human immunodeficiency virus patients after
enya, Journal of Microbiology, Immunology and Infection (2015),
Table 1 Clinical information on Kaposi’s sarcoma patients
(cases).
Clinical information KS patients (cases)
N Z 33
n %
Chemotherapy
Yes 19 57.6
No 14 42.4
Comorbidities
Yes 8 24.2
No 25 75.8
Latest CD4 count (cells/mm3)
 300 7 21.2
< 300 26 78.8
Site of KS lesions
Visceral 5 15.2
Lower limbs 15 45.5
Trunk 10 30.3
Others 3 9.1
KSZ Kaposi’s sarcoma.
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were included in our study. We then performed a matched
caseecontrol study. Cases and controls were matched in
the ratio of 1:4 based on age (5 years of each case), sex,
and KS diagnosis date using the propensity score matching
function in SPSS (SPSS Inc., Chicago, IL, USA). The diagnosis
day for the control group referred to the day on which their
matched case was diagnosed to have KS. In total, 165 par-
ticipants (33 cases and 132 controls) were included in the
final analysis. The study protocol was approved by the
Maseno Hospital Ethics and Research Committee. All the
cases were anonymized.
Adherence assessment
For patients’ adherence to HAART, there are two kinds of
information recorded in the database: “perfect adherence”
and “loss to follow-up.” Adherence to HAART was assessed
on every clinic visit by patients’ self-reporting and pill
counts. Pill counts are typically measured by counting the
quantity of the remaining doses of medication and assuming
that these remaining excess pills represent missed doses.
Adherence was considered “perfect” when patients’
self-reporting and pill counts indicated that they had taken
all of the doses of drugs at every visit since starting HAART.
A patient was defined as “lost to follow-up” if he or she had
not returned to the clinic or pharmacy for a scheduled drug
pickup more than 90 days after the drug appointment. In
the event that the patient missed an appointment for refills
in the stated period, it was assumed that the patient was
not taking the medication or was missing doses.
Information related to KS and adherence
We collected participators’ demographic information
including their age at enrollment, age at initiation of ART,
sex, educational level, occupation, and health-risk
behavior as the number of regular sexual partners in their
lifetime (by self-disclosure). Potential risk factors,
including participators’ latest CD4 count, initial WHO stage,
and distance to the health-care facility, were also collected
for further analysis.
Statistical analysis
Age at enrollment, age at initiation of ART, time from
enrollment to event outcome, and the latest CD4 count
were compared between cases and controls by a Wilcoxon
rank-sum test. For cases, time from enrollment to event
outcome means the time from enrollment to diagnosis. For
controls, time from enrollment to event outcome means
the time from enrollment to the date their matched cases
were diagnosed to have KS. Socioeconomic and clinical
statuses, including sex, educational level, occupation,
distance to the health-care facility, number of regular
sexual partners, and initial WHO stage, and patients’ per-
fect adherence, loss to follow up, and death were
compared between cases and controls by a Chi-square test.
While the average number of regular sexual partners of our
samples is 3.2, we used the cut number as three in our
analysis. A conditional logistic regression for paired dataPlease cite this article in press as: Lupia R, et al., Risk factors for K
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http://dx.doi.org/10.1016/j.jmii.2015.10.009was used to assess the effects of the variables including
education level, latest CD4 count, initial WHO stage, per-
fect adherence to HAART, and number of regular sexual
partners on the development of KS. Because of overlapping
concepts, we only run the regression for “perfect adher-
ence to HAART” because it was more sensitive than the
variable “lost to follow-up.” A multivariate analysis was
performed by fitting a stratified Cox model to matched
pairs to adjust for potential imbalances in the baseline and
clinical characteristics for both cases and controls [16].
Results are reported as the multivariate adjusted and un-
adjusted hazard ratios (HRs) with 95% confidence intervals
(CIs) for associations between predicting variables and the
outcome. The analysis was carried out using SPSS 18.0
software (SPSS Inc.). A probability level of p Z 0.05 was
used to determine statistical significance.
Results
Demographic and disease characteristics of KS
patients
Table 1 illustrates the clinical information of KS patients
(cases) in our study. Of the 33 KS cases, 19 (57.6%) had
received chemotherapy plus HAART, and 14 patients
(42.4%) had received only HAART. Among the 33 KS cases,
eight patients had KS and other comorbidities, while
tuberculosis was the most common comorbidity among
them (6 patients with it). The remaining two cases had
Pneumocystis pneumonia.
The eight KS patients with comorbidities also had an
average CD4 count of 35 cells/mm3. In addition, of the
33 KS cases, the CD4 counts of seven patients were 
300 cells/mm3. Furthermore, the anatomical sites of all the
33 KS cases were known. The commonest sites among these
33 KS cases were the lower limbs and trunk, which
accounted for 75% of cases.aposi’s sarcoma in human immunodeficiency virus patients after
enya, Journal of Microbiology, Immunology and Infection (2015),
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and the control group
Table 2 compares demographic data between patients who
developed KS and the control group. Among the 165Table 2 Comparisons of sociodemographic characteristics, clin
Total
N Z 165
Median (IQR)
Age at enrollment (y) 35.4 (30.6e49.3)
Age at HAART start (y) 35.6 (30.8e49.5)
Time from enrollment to event outcome (mo) 15.2 (11.0e26.4)
Latest CD4 count (cells/mm3) a 314.4 (232.6e422
n %
Sex
Male 80 48.5
Female 85 51.5
Educational level
Illiterate 25 15.2
Primary 102 61.8
Secondary 11 6.7
Tertiary b 27 16.4
Occupation
Employed 29 17.6
Farmer 35 21.2
Housewife 18 10.9
Self-employed 53 32.1
Student 3 1.8
Unemployed 27 16.4
Distance to health facility (km)
0e10 91 55.2
11e20 30 18.2
>20 24 14.5
Unknown 20 12.1
Initial WHO stage
Low (Stage 1 or 2) 78 47.3
High (Stage 3 or 4) 87 52.7
Number of regular sexual partners in lifetime
 2 66 40.0
> 3 63 38.2
HAART perfect adherence
Yes 105 63.6
No 60 36.4
Lost to follow up
Yes 58 35.2
No 107 64.8
Death c
Yes 31 18.8
No 134 81.2
a Latest CD4 count was evaluated at the time of Kaposi’s sarcoma (K
was diagnosed with KS for controls.
b College level and above.
c By the end of 2013.
HAART Z highly active antiretroviral therapy; IQR Z interquartile ra
* p < 0.05.
** p < 0.001.
*** p < 0.01.
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http://dx.doi.org/10.1016/j.jmii.2015.10.009participants (33 cases and 132 controls) included in the final
analysis, 48.5% were men and 51.5% were women. The
overall median age at enrollment was 35.4 years. The me-
dian age for cases and controls was similar. In general, the
median age at initiation of HAARTwas 35.6 years. The total
median time from enrollment to event outcome (diagnosisical status and adherence between Cases and Controls.
Cases Controls p
N Z 33 N Z 132
Median (IQR) Median (IQR)
35.0 (29.0e47.5) 35.5 (31.0e49.8) 0.142
36.0 (30.0e48.5) 35.5 (31.0e49.8) 0.22
12.0 (11.0e24.0) 16.0 (11.0e27.0) 0.081
.2) 170.0 (62.0e289.0) 353.0 (277.0e455.0) < 0.001 *
n % n %
16 48.5 64 48.5 0.716
17 51.5 68 51.5
12 36.4 13 9.8 0.545
12 36.4 90 68.2
4 12.1 7 5.3
5 15.2 22 16.7
4 12.1 25 18.9 0.954
4 12.1 31 23.5
3 9.1 15 11.4
11 33.3 42 31.8
0 0.0 3 2.3
11 33.3 16 12.1
21 63.6 70 53.0 0.416
5 15.2 25 18.9
4 12.1 20 15.2
3 9.1 17 12.9
8 24.2 70 53.0 0.706
25 75.8 62 47.0
11 33.3 64 48.5 < 0.001 **
22 66.7 68 51.5
6 18.2 99 75.0 < 0.001 **
27 81.8 33 25.0
13 39.4 45 34.1 < 0.001 **
20 60.6 87 65.9
11 33.3 20 15.2 0.003 ***
22 66.7 112 84.8
S) diagnosis for the cases and at the last visit date when the case
nge; WHOZWorld Health Organization.
aposi’s sarcoma in human immunodeficiency virus patients after
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between enrollment into the program and initiation of ART
was 1 year (data not shown). In addition, participants had a
median latest CD4 count of 314.4 cells/mm3. Compared
with the control group, KS patients had a statistically sig-
nificant lower CD4 count at the time of their diagnosis.
The majority of KS cases in our study were illiterate
(36.4%), whereas the majority of the control group had a
primary school education (68.2%). However, the difference
in educational level between the two groups of patients
was not significant. Most of the KS patients were either
unemployed or self-employed, whereas most patients in
the control group were self-employed (31.8%). In addition,
the majority of KS patients lived near the health-care fa-
cility (63.6%), whereas only 53.0% of patients in the con-
trol group lived nearby, however, the difference between
the two groups was insignificant. Regarding the initial WHO
staging, most of the cases were categorized as having
initial WHO Stage 3 or 4 (75.8%), whereas most of the
patients in the control group had lower initial WHO Stages
of 1 or 2 (53.0%). In addition, our KS patients had signifi-
cantly more regular sexual partners than patients in the
control group, as the majority of KS patients (66.7%) had
had more than three regular sexual partners in their
lifetime.Table 3 Associations between adherence, sociodemographic c
conditional logistic regression.
Variables
Unadjusted
HR 95% CI p
Educational level
Tertiary a 1
Illiterate 1.43 0.5e4.2 0
Primary 0.51 0.2e1.5 0
Secondary 1.00 0.3e4.0 0
Distance to health-care facility (km)
0e10 1
11e20 1.2 0.3e4.0 0
> 20 1.1 0.3e4.5 0
Unknown 2.3 0.5e11.2 0
Initial WHO stage
Low (Stage 1 or 2) 1
High (Stage 3 or 4) 1.4 0.6e3.5 0
Latest CD4 count (cells/mm3)
> 350 1
 350 3.1 1.1e8.5 0
Number of regular sexual partners in lifetime
 2 1
> 3 1.6 0.8e3.4 0
HAART perfect adherence
Yes 1
No 6.2 2.4e15.7 < 0
a College level and above.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
CI Z confidence interval; HAART Z highly active antiretroviral ther
Health Organization.
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ence in our study. Compared with KS patients (cases), pa-
tients in the control group had a significantly higher
percentage of perfect adherence (75.0%). Correspondingly,
the overall percentage of “loss to follow-up” was 39.4%. In
addition, patients in the control group showed a significantly
lower percentage of “loss to follow-up” than did KS patients
(34.0% vs. 39.4%). Compared with the control group, more KS
patients died during our study period (33.3%).
Associations of adherence, sociodemographic
characteristics, and clinical status with the
development of KS by conditional logistic
regression
Results of the multivariate model are shown in Table 3.
From the study results, imperfect HAART adherence was
found to be significantly associated with KS development.
Before adjustment, patients with imperfect HAART adher-
ence had a six-time higher risk of developing KS than pa-
tients with perfect HAART adherence (HRs: 6.2, 95% CI:
2.4e15.7). After adjustment, patients with imperfect
HAART adherence had a 20-fold greater risk of developing
KS than patients with perfect HAART adherence (HRs: 21.0,
95% CI: 4.2e105.1).haracteristics, clinical status, and development of KS by a
Development of KS
Adjusted
HR 95% CI p
1
.518 1 0.1e10.6 0.985
.224 0.2 0.0e1.2 0.068
.997 0.5 0.0e8.0 0.619
.824 1.1 0.1e10.8 0.937
.948 1.3 0.1e14.7 0.844
.294 4.7 0.3e66.4 0.249
1
.424 1.7 0.5e6.3 0.397
1
.03 * 7.1 1.4e36.2 0.018 *
1
.2 4.2 0.8e21.4 0.087
1
.001 *** 21.0 4.2e105.1 < 0.001 ***
apy; HR Z hazard ratio; KS Z Kaposi’s sarcoma; WHO Z World
aposi’s sarcoma in human immunodeficiency virus patients after
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significantly associated with KS development, and the HRs
were 7.1 (95% CI: 1.4e36.2) after adjustment. None of the
other covariates, including educational level, initial WHO
stage, distance to the health-care facility, and number of
regular sexual partners (lifetime), was associated with the
development of KS, even after adjustments.Discussion
To our knowledge, this is the first study to examine the
associations of adherence to HAART treatment and the
development of KS in HIV/AIDS patients. Our analysis
revealed important predictors for KS development among
HIV-positive individuals. From the study results, we found a
low HAART adherence rate as well as a significant associa-
tion between imperfect HAART adherence and the risk of
developing KS among AIDS patients. We also observed that a
low latest CD4 count ( 350 cells/mm3) was statistically
associated with the risk of KS development.
Our study results show that imperfect adherence to ART
treatment is a predictor of KS development among AIDS
patients. This might be due to their weakened immune
systems, which are considered deficient and hence can no
longer fulfill their role of fighting KS-associated herpes virus
(KSHV). Based on our study results, we suggest that HIV
prevention programs adopt an approach such as the one
used in tuberculosis control programs to improve adherence
rates among individuals. Interventions toward antiretroviral
adherence mostly reported in the literature are inclined
toward dedicating time with patients to plan for and sup-
port medication adherence.20e22 The nature and regularity
of these interventions vary, but those that seem effective
are characterized by an initial educational session including
tailored collaborative medication planning with follow-up
sessions maintained regularly over the course of treat-
ment.21,23 With previous successful findings, improved
counseling with follow up by social health workers to
monitor pill intake can be a step forward to strengthen the
adherence to HAART by KS patients.
In addition, patients with a latest CD4 count of 
350 cells/mm3 had a seven-time greater risk of developing
KS than patients with a CD4 count of > 350 cells/mm3. This
is because opportunistic infections typically begin to affect
individuals when CD4 counts fall below 350 cells/mm3.24 In
addition, this outcome echoed previous observational
studies and randomized controlled trials, which reported
increased morbidity, mortality, immunological, and viro-
logical outcomes when initiating treatment in cases where
the CD4 count was  350 cells/mm3; by contrast, initiating
HAART at a CD4 count of > 350 cells/mm3 reduced the risk
of progression to AIDS and death or development of AIDS-
defining illnesses like KS.25
Interestingly, the persistence or development of KS in
HIV-infected patients on HAART despite high CD4 counts
was reported by several researchers.26e29 This phenomenon
was also observed in our study in which seven of our pa-
tients were diagnosed with KS when they had a CD4 count
of > 300 cells/mm3. Empirical research suggests that this
phenomenon might have resulted from other social be-
haviors such as high rates of drug use and imperfectPlease cite this article in press as: Lupia R, et al., Risk factors for K
initiation of antiretroviral therapy: A nested caseecontrol study in K
http://dx.doi.org/10.1016/j.jmii.2015.10.009antiretroviral adherence.30,31 It is also important to note
that the population of Maseno where this study was con-
ducted has a high rate of drug abuse.32 Nevertheless,
further study is needed to understand relationships among
CD4 counts, the development of KS, and the possible causes
for this phenomenon.
From our study results, the risk of developing KS in-
creases when the initial WHO sequence progressed to
Stages 3 and 4. However, an association was not found
between the initial WHO clinical stage and development of
KS. The WHO staging of patients was only done once during
enrollment in the program, which might be a possible
explanation for this phenomenon. An association between
KS development and educational level was not found in our
study, although the impact of education on adherence was
confirmed by previous studies.33e35 This can be attributed
to the small sample size of our patients. However, the
importance of education cannot be overlooked, as empir-
ical studies have shown that patients with limited literacy
might be unwilling to ask for assistance to take medicines
appropriately.36 In addition, though the risk of developing
KS increased as the distance exceeded 10 km from the HIV/
AIDS clinic, the association was not statistically significant.
A plausible explanation for this phenomenon might be
because the majority of patients in our study lived near the
facility. While other studies found that travel time and
access to treatment centers were barriers to ART adher-
ence, distance cannot be disregarded in preventing
imperfect adherence to medication.37
The absence of associations between KS development
and the number of regular sexual partners (in one’s life-
time) in our study might reiterate the lack of evidence for
sexual activity as a major route of KSHV transmission, while
other routes of transmission, such as through saliva or blood
contact, were pointed out by previous studies.38 However,
the role of sexual behavior cannot be disregarded, and
further studies are needed to understand the relationship
between sexual partners and KS development.
There are some limitations to this study. First, baseline
viral load testing is not routinely done in this setting. A
number of studies indicated that controlling the HIV viral
load is essential for clinical improvement, disease resolu-
tion of KS, and perhaps decreased risk of relapse. While the
information on viral load is not available to represent a
patient’s accurate immune status, we might have over-
estimated KS patents’ immune statuses in our study. Sec-
ond, the number of sex partners was evaluated by self-
reporting, and there may have been a self-bias in this,
therefore, we might have underestimated the impact of
this factor. Third, we may have underestimated the
severity of AIDS patient’s imperfect adherence due to the
fact that adherence was based on patients’ self-reporting
and pill counts, which were also provided by patients.
In conclusion, imperfect adherence to ART and a low CD4
count were found to be associated with the development of
KS in our study. While a low adherence rate was also found
in our study, we suggest the urgent need of policies to
improve the adherence of patients undergoing ART treat-
ment to prevent KS development. Although the multifac-
torial nature of imperfect adherence means that there will
never be a universal solution, it is imperative for policy-
makers to come up with intervention programs that canaposi’s sarcoma in human immunodeficiency virus patients after
enya, Journal of Microbiology, Immunology and Infection (2015),
HAART adherence and Kaposi’s sarcoma in HIV/AIDS patients 7
+ MODELimprove patients’ awareness of the importance of adher-
ence through regular counseling.Conflicts of interest
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